Planning For Exchanges: Pharma Hopes For “Broad Enrollment,” But Timeline Causes Concern
For pharmaceutical companies, the barometer for measuring success of the health plan exchanges created under the health care reform law will be how well they encourage broad enrollment.
You may also be interested in...
CMS Budget Plan: $1 Bil. Increase For Administrative Activities Is New, But Drug Policy Proposals Are Old
CMS budget plan reprises Medicare drug rebates for dual eligibles, eliminating brand/generic patent settlements and other unsuccessful Rx proposals.
Medicare-sanctioned accountable care organizations could significantly improve drug adherence among beneficiaries as a way to prevent more costly medical interventions later, under a widely-anticipated CMS proposal.
PhRMA was among a number of stakeholders presenting comments Jan. 14 to the committee on criteria and methods for determining and updating what qualifies as "essential health benefits" in the exchange plans.